INSYS

INSYS icom Designates CITIC Telecom CPC as Selected Partner For Asia and China Markets Expansion and Industrial Internet of Things (IIoT) Transformation

Retrieved on: 
Tuesday, January 16, 2024
Private, LAN, Cloud computing, Geography, CITIC Telecom International, GDPR, Culture, INSYS, Knowledge, Partnership, VPN, Managed services, Water supply, Government, Premium, Communication, SIM, Industrial, Industrial internet of things, CITIC Telecom CPC, Plant, VPLS, Internet of things, Mobile phone

HONG KONG, Jan 16, 2024 - (ACN Newswire) - CITIC Telecom International CPC Limited ("CITIC Telecom CPC"), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce INSYS icom has designated CITIC Telecom CPC as the handpicked partner to support INSYS icom's expansion into the Asia and China markets.

Key Points: 
  • HONG KONG, Jan 16, 2024 - (ACN Newswire) - CITIC Telecom International CPC Limited ("CITIC Telecom CPC"), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce INSYS icom has designated CITIC Telecom CPC as the handpicked partner to support INSYS icom's expansion into the Asia and China markets.
  • Secure communication and networking of data in industrial applications - that is the core competence of INSYS icom.
  • As the selected partner, CITIC Telecom CPC is facilitating INSYS icom in this business growth initiative via both technological and business assistance.
  • With CITIC Telecom CPC's services and expertise, INSYS icom is now continuing to develop other new applications and extend functionality for customers within existing markets and new geographies.

BrainStorm Appoints William K. White as Senior Vice President, Head of Market Access & Pricing

Retrieved on: 
Tuesday, September 29, 2020
Life sciences, Industries, Companies, Novartis, Insys Therapeutics, INSYS, Medication

NEW YORK, Sept. 29, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment of William K. White as senior vice president, head of market access and pricing.Mr.

Key Points: 
  • NEW YORK, Sept. 29, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the appointment of William K. White as senior vice president, head of market access and pricing.Mr.
  • White has more than 25 years' experience in leading successful product commercialization and securing market access for innovative new medicines.
  • Mr. White was most recently Vice President of Patient and Market Access at Avexis, now Novartis Gene Therapies.
  • Mr. White has also held leadership positions in managed care and patient access at Insys Therapeutics and Lundbeck (formerly Ovation Pharmaceuticals).

Kessler Topaz Meltzer & Check, LLP Announces Proposed Partial Settlement of the Insys Therapeutics, Inc. Securities Litigation

Retrieved on: 
Monday, August 17, 2020
Insys Therapeutics, Opioid epidemic, INSYS, Civil procedure, Lawsuit, Motion, Civil law, South African law, Economy of the United States, Law, Government, Civil procedure in South Africa

This notice provides only a summary of the information contained in the detailed Notice of (I)Proposed Settlement with Defendant Michael L. Babich; (II) Settlement Fairness Hearing; and (III) Motion for Litigation Expenses ("Settlement Notice").

Key Points: 
  • This notice provides only a summary of the information contained in the detailed Notice of (I)Proposed Settlement with Defendant Michael L. Babich; (II) Settlement Fairness Hearing; and (III) Motion for Litigation Expenses ("Settlement Notice").
  • You may obtain a copy of the Settlement Notice, along with the Claim Form, on the website for the Action, www.InsysRXSecuritiesLitigation.com .
  • You may also obtain a copy of the Settlement Notice and the Claim Form by writing to the Claims Administrator at Insys Therapeutics, Inc. Securities Litigation, c/o A.B.
  • Requests for the Settlement Notice and Claim Form should be made to the Claims Administrator:

Kessler Topaz Meltzer & Check, LLP Announces Proposed Partial Settlement of the Insys Therapeutics, Inc. Securities Litigation

Retrieved on: 
Monday, July 20, 2020
Insys Therapeutics, Opioid epidemic, Civil law, Lawsuit, INSYS, Settlement, Economy of the United States, Companies, Class action

If approved, the Settlement will resolve all claims in the Action against Defendant Kapoor only.

Key Points: 
  • If approved, the Settlement will resolve all claims in the Action against Defendant Kapoor only.
  • Please Note: This settlement does not resolve any of the claims asserted against the other defendants in the Action.
  • You may also obtain a copy of the Settlement Notice and the Claim Form by writing to the Claims Administrator at Insys Therapeutics, Inc. Securities Litigation, c/o A.B.
  • Your Baker Settlement Claim Form will also beprocessed in connection with this Settlement.

Kessler Topaz Meltzer & Check, LLP Announces Proposed Partial Settlement of the Insys Therapeutics, Inc. Securities Litigation

Retrieved on: 
Monday, June 22, 2020
INSYS, Lawsuit, Civil procedure, South African law, Civil law, Economy of the United States, Companies, Civil procedure in South Africa

This notice provides only a summary of the information contained in the detailed Notice of (I)Proposed Settlement with Defendant Darryl S. Baker; (II) Settlement Fairness Hearing; and (III) Motion for Litigation Expenses ("Settlement Notice").

Key Points: 
  • This notice provides only a summary of the information contained in the detailed Notice of (I)Proposed Settlement with Defendant Darryl S. Baker; (II) Settlement Fairness Hearing; and (III) Motion for Litigation Expenses ("Settlement Notice").
  • You may obtain a copy of the Settlement Notice, along with the Claim Form, on the website for the Action, www.InsysRXSecuritiesLitigation.com .
  • You may also obtain a copy of the Settlement Notice and the Claim Form by writing to the Claims Administrator at Insys Therapeutics, Inc. Securities Litigation, c/o A.B.
  • Requests for the Settlement Notice and Claim Form should be made to the Claims Administrator:

Global Opioids Market - Growth, Trends and Forecasts (2019-2024): Rising Focus on Abuse-deterrent Formulation (ADF) by Generic Manufacturers - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 9, 2019
Health, Pharmaceutical, Companies, Pharmaceutical companies, Science and technology in Israel, Teva Pharmaceutical Industries, Amneal Pharmaceuticals, Allergan, Opioid, INSYS, Mallinckrodt, Industries

Due to an increase in the incidence of medical ailments, the market studied is expected to grow over the forecast period.

Key Points: 
  • Due to an increase in the incidence of medical ailments, the market studied is expected to grow over the forecast period.
  • In the receptor binding segment of the opioids market, the strong agonist category is expected to have the largest market size.
  • North America currently dominates the market for opioids and is expected to continue its strong hold for a few more years.
  • Allergan, Teva Pharmaceuticals, Mallinckrodt, Insys Therapeutics, and Amneal Pharmaceuticals Inc. hold a substantial market share of the opioids market.

Whistleblower case that convinced government to investigate Insys Therapeutics is publicly revealed for first time

Retrieved on: 
Tuesday, May 15, 2018
Anti-corporate activism, Dissent, Freedom of speech, Labour law, Whistleblower, Workplace bullying, INSYS, Terminology, Business, Law

The former sales rep, Maria Guzman, is represented by Phillips & Cohen LLP and the Law Office of Mark Kleiman.

Key Points: 
  • The former sales rep, Maria Guzman, is represented by Phillips & Cohen LLP and the Law Office of Mark Kleiman.
  • The federal district court in Los Angeles unsealed, and therefore made public for the first time, Guzman's lawsuit and other whistleblower lawsuits against Insys that were filed after Guzman's case.
  • After she complained about the company's tactics to persuade doctors to prescribe and overprescribe Subsys, Insys fired her in July 2013.
  • Insys paid doctors thousands of dollars each in "speaking fees" for attending dinners that might have just one other person.